Genitourinary Cancers | Topics

 
Trimodal Pembrolizumab-Based Combo Shows Safety and Efficacy Treating MIBC
June 08, 2021

Pembrolizumab plus gemcitabine and concurrent hypofractionated radiotherapy to treat patients with MIBC demonstrated safety and efficacy.

Nivolumab Granted Priority Review as Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma
April 30, 2021

Based on results of the recently reported phase 3 CheckMate 274 trial, the FDA has granted priority review designation to nivolumab for the adjuvant treatment of high-risk muscle-invasive bladder cancer.

ODAC Decision Means Atezolizumab Will Maintain It’s Indication for Frontline Urothelial Carcinoma
April 29, 2021

Accelerated approval for atezolizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for certain chemotherapy regimens was maintained by an FDA committee vote.